This inventor holds 4 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Pharma Co., Ltd.. Active years: 2017-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2024
Title: Masafumi Komiya: Innovator in Medicinal Chemistry
Introduction
Masafumi Komiya is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds related to orexin receptors. With a total of 4 patents to his name, his work has the potential to impact the treatment of various sleep-related disorders.
Latest Patents
Komiya's latest patents include a cycloalkylurea derivative, which is a medicament designed for treating or preventing diseases associated with orexin receptors, especially the orexin type 2 receptor. This innovative compound features a urea structure or a pharmaceutically acceptable salt as its active ingredient. The invention specifically targets conditions such as narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea syndrome.
Career Highlights
Throughout his career, Masafumi Komiya has worked with prominent companies in the pharmaceutical industry, including Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and medicinal chemistry.
Collaborations
Komiya has collaborated with esteemed colleagues, including Keiji Adachi and Eiji Ideue. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Masafumi Komiya's innovative work in medicinal chemistry, particularly in the area of orexin receptor-related treatments, showcases his dedication to improving healthcare solutions. His contributions are significant in the ongoing quest to address sleep disorders effectively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile